These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 9140445)

  • 1. Comparison of efficacies of ondansetron and dixyrazine for prophylaxis of emesis during induction treatment in acute myelogenous leukemia. A pilot study.
    Sundström GM; Wahlin A
    Acta Oncol; 1997; 36(2):229-30. PubMed ID: 9140445
    [No Abstract]   [Full Text] [Related]  

  • 2. Single 8 mg dose of oral ondansetron failed to prevent FAC chemotherapy-induced acute nausea and vomiting.
    Bosnjak SM; Neskovic-Konstantinovic ZB; Jovanovic-Micic DJ; Mitrovic LB; Radulovic SS
    J Chemother; 1996 Aug; 8(4):315-8. PubMed ID: 8873840
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preliminary experience with use of a selective 5HT3 receptor antagonist (ondansetron) to prevent high dose chemotherapy induced emesis.
    Parikh PM; Shah SR; Shah SC; Sheth V; Patel RA; Shah KC; Jain PK
    Indian J Cancer; 1996 Mar; 33(1):17-20. PubMed ID: 9063013
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serotonin receptor antagonists in prophylaxis of acute and delayed emesis induced by moderately emetogenic, single-day chemotherapy: a randomized study.
    Yalçin S; Tekuzman G; Baltali E; Ozişik Y; Barişta I
    Am J Clin Oncol; 1999 Feb; 22(1):94-6. PubMed ID: 10025391
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antiemetic efficacy of three serotonin antagonists during high-dose chemotherapy and autologous stem cell transplantation in malignant lymphoma.
    Slabý J; Trnený M; Procházka B; Klener P
    Neoplasma; 2000; 47(5):319-22. PubMed ID: 11130251
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Efficacy of ondansetron in acute and delayed cisplatin-induced nausea and vomiting].
    Depierre A
    Bull Cancer; 1996 Feb; 83(2):147-53. PubMed ID: 8652909
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of ABCB1 polymorphisms with the efficacy of ondansetron in chemotherapy-induced nausea and vomiting.
    He H; Yin JY; Xu YJ; Li X; Zhang Y; Liu ZG; Zhou F; Zhai M; Li Y; Li XP; Wang Y; Zhou HH; Liu ZQ
    Clin Ther; 2014 Aug; 36(8):1242-1252.e2. PubMed ID: 25012726
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevention of cyclophosphamide/cytarabine-induced emesis with ondansetron in children with leukemia.
    Carden PA; Mitchell SL; Waters KD; Tiedemann K; Ekert H
    J Clin Oncol; 1990 Sep; 8(9):1531-5. PubMed ID: 2144019
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessment of chemotherapy-induced emesis and evaluation of a reduced-dose intravenous ondansetron regimen in pediatric outpatients with leukemia.
    Holdsworth MT; Raisch DW; Duncan MH; Chavez CM; Leasure MM
    Ann Pharmacother; 1995 Jan; 29(1):16-21. PubMed ID: 7711340
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Meta-analysis of phase III studies with palonosetron in the prevention of vomiting induced by moderately emetogenic chemotherapy].
    Di Maio M; Gallo C; Perrone F
    Tumori; 2008; 94(2):suppl 14-22. PubMed ID: 18564621
    [No Abstract]   [Full Text] [Related]  

  • 11. 5-HT3 receptor antagonists in the control of cisplatin-induced delayed emesis.
    Ossi M; Anderson E; Freeman A
    Oncology; 1996 Jun; 53 Suppl 1():78-85. PubMed ID: 8692556
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Recent improvements in antiemetic therapy].
    Roila F; Palladino MA; Ciccarese G; Basurto C
    Tumori; 1997; 83(2 Suppl):S3-14. PubMed ID: 9235727
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 5-HT3 receptor antagonists in the prophylaxis of acute vomiting induced by moderately emetogenic chemotherapy--a randomised study.
    Jantunen IT; Muhonen TT; Kataja VV; Flander MK; Teerenhovi L
    Eur J Cancer; 1993; 29A(12):1669-72. PubMed ID: 8398291
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of ondansetron with customary treatment in the prophylaxis of nausea and emesis induced by non-cisplatin containing chemotherapy.
    Jantunen IT; Flander MK; Heikkinen MI; Kuoppala TA; Teerenhovi L; Kataja VV
    Acta Oncol; 1993; 32(4):413-5. PubMed ID: 8369129
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effectiveness of serotonin-receptor antagonist antiemetic therapy over successive courses of carboplatin-based chemotherapy.
    Markman MR; Peterson G; Kulp B; Markman M
    Gynecol Oncol; 2002 Jun; 85(3):435-7. PubMed ID: 12051870
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative efficacy of a single oral dose of ondansetron and of buspirone against cisplatin-induced emesis in cancer patients.
    Alfieri AB; Cubeddu LX
    Br J Cancer; 1995 Oct; 72(4):1013-5. PubMed ID: 7547213
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Double-blind, randomized comparison of the antiemetic efficacy of intravenous dolasetron mesylate and intravenous ondansetron in the prevention of acute cisplatin-induced emesis in patients with cancer. Dolasetron Comparative Chemotherapy-induced Emesis Prevention Group.
    Hesketh P; Navari R; Grote T; Gralla R; Hainsworth J; Kris M; Anthony L; Khojasteh A; Tapazoglou E; Benedict C; Hahne W
    J Clin Oncol; 1996 Aug; 14(8):2242-9. PubMed ID: 8708713
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antagonism of serotonin S3 receptors with ondansetron prevents nausea and emesis induced by cyclophosphamide-containing chemotherapy regimens.
    Cubeddu LX; Hoffman IS; Fuenmayor NT; Finn AL
    J Clin Oncol; 1990 Oct; 8(10):1721-7. PubMed ID: 2145400
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomised comparison of ondansetron and metoclopramide plus dexamethasone for chemotherapy induced emesis.
    Dick GS; Meller ST; Pinkerton CR
    Arch Dis Child; 1995 Sep; 73(3):243-5. PubMed ID: 7492164
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Efficacy of granisetron for preventing chemotherapy-induced nausea and vomiting in patients with acute myelogenous leukemia treated with a combination of anthracycline and cytarabine].
    Goto T; Tanimoto K; Ishibashi M; Okamura S
    Gan To Kagaku Ryoho; 2012 Aug; 39(8):1227-32. PubMed ID: 22902447
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.